LYRA Relative Valuation
LYRA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LYRA is overvalued; if below, it's undervalued.
Historical Valuation
Lyra Therapeutics Inc (LYRA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.14. The fair price of Lyra Therapeutics Inc (LYRA) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：4.19
Fair
-0.54
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Lyra Therapeutics Inc. (LYRA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.95. The thresholds are as follows: Strongly Undervalued below -3.57, Undervalued between -3.57 and -2.26, Fairly Valued between 0.35 and -2.26, Overvalued between 0.35 and 1.66, and Strongly Overvalued above 1.66. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.41
EV/EBIT
Lyra Therapeutics Inc. (LYRA) has a current EV/EBIT of -0.41. The 5-year average EV/EBIT is -0.77. The thresholds are as follows: Strongly Undervalued below -2.83, Undervalued between -2.83 and -1.80, Fairly Valued between 0.25 and -1.80, Overvalued between 0.25 and 1.28, and Strongly Overvalued above 1.28. The current Forward EV/EBIT of -0.41 falls within the Historic Trend Line -Fairly Valued range.
7.08
PS
Lyra Therapeutics Inc. (LYRA) has a current PS of 7.08. The 5-year average PS is 85.42. The thresholds are as follows: Strongly Undervalued below -90.47, Undervalued between -90.47 and -2.52, Fairly Valued between 173.36 and -2.52, Overvalued between 173.36 and 261.30, and Strongly Overvalued above 261.30. The current Forward PS of 7.08 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Lyra Therapeutics Inc. (LYRA) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.29. The thresholds are as follows: Strongly Undervalued below -8.19, Undervalued between -8.19 and -4.74, Fairly Valued between 2.16 and -4.74, Overvalued between 2.16 and 5.60, and Strongly Overvalued above 5.60. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.16
P/FCF
Lyra Therapeutics Inc. (LYRA) has a current P/FCF of -0.16. The 5-year average P/FCF is -1.70. The thresholds are as follows: Strongly Undervalued below -4.44, Undervalued between -4.44 and -3.07, Fairly Valued between -0.33 and -3.07, Overvalued between -0.33 and 1.04, and Strongly Overvalued above 1.04. The current Forward P/FCF of -0.16 falls within the Overvalued range.
Lyra Therapeutics Inc (LYRA) has a current Price-to-Book (P/B) ratio of -1.59. Compared to its 3-year average P/B ratio of 1.75 , the current P/B ratio is approximately -190.95% higher. Relative to its 5-year average P/B ratio of 1.82, the current P/B ratio is about -187.63% higher. Lyra Therapeutics Inc (LYRA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -289.81%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -183.67% , the current FCF yield is about -100.00% lower.
-1.71
P/B
Median3y
1.75
Median5y
1.82
-458.63
FCF Yield
Median3y
-289.81
Median5y
-183.67
Competitors Valuation Multiple
The average P/S ratio for LYRA's competitors is 0.00, providing a benchmark for relative valuation. Lyra Therapeutics Inc Corp (LYRA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -87.18%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of LYRA decreased by 56.40% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -6.09K to -23.94K.
The secondary factor is the Revenue Growth, contributed -87.18%to the performance.
Overall, the performance of LYRA in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Lyra Therapeutics Inc (LYRA) currently overvalued or undervalued?
What is Lyra Therapeutics Inc (LYRA) fair value?
How does LYRA's valuation metrics compare to the industry average?
What is the current P/B ratio for Lyra Therapeutics Inc (LYRA) as of Dec 05 2025?
What is the current FCF Yield for Lyra Therapeutics Inc (LYRA) as of Dec 05 2025?
What is the current Forward P/E ratio for Lyra Therapeutics Inc (LYRA) as of Dec 05 2025?